SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS FROM A PHASE III RANDOMISED TRIAL

Renal Cell ◽

Randomised Trial ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

4509 POSTER Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71140-0 ◽

2007 ◽

Vol 5 (4) ◽

pp. 301 ◽

Cited By ~ 8

Author(s):

R.J. Motzer ◽

M.D. Michaelson ◽

T.E. Hutson ◽

P. Tomczak ◽

R.M. Bukowski ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

BMC Cancer ◽

10.1186/s12885-016-3016-4 ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 12

Author(s):

Hai-Liang Zhang ◽

Xi-Nan Sheng ◽

Xue-Song Li ◽

Hong-Kai Wang ◽

Zhi-Hong Chi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Cell Carcinoma ◽

Retrospective Analysis ◽

Renal Cell ◽

Chinese Patients ◽

Line Treatment ◽

First Line ◽

A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma

European Urology ◽

10.1016/j.eururo.2021.03.016 ◽

2021 ◽

Author(s):

Irbaz Bin Riaz ◽

Huan He ◽

Alexander J. Ryu ◽

Rabbia Siddiqi ◽

Syed Arsalan Ahmed Naqvi ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Line Treatment ◽

First Line ◽

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdz249.052 ◽

2019 ◽

Vol 30 ◽

pp. v386-v387

Author(s):

M. Uemura ◽

Y. Tomita ◽

H. Miyake ◽

S. Hatakeyama ◽

H.-O. Kanayama ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Subgroup Analysis ◽

Renal Cell ◽

Phase Iii ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma

PharmacoEconomics ◽

10.1007/s40273-012-0006-5 ◽

2012 ◽

Vol 31 (1) ◽

pp. 15-24 ◽

Cited By ~ 21

Author(s):

Mary Kilonzo ◽

Jenni Hislop ◽

Andrew Elders ◽

Cynthia Fraser ◽

Donald Bissett ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES

Current Opinion in Urology ◽

10.1097/mou.0000000000000207 ◽

2015 ◽

Vol 25 (5) ◽

pp. 395-401 ◽

Cited By ~ 6

Author(s):

Manuela Schmidinger ◽

Janet Wittes

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

How does vaccine treatment compare with standard targeted therapy for first-line treatment of people with metastatic renal cell carcinoma?

Cochrane Clinical Answers ◽

10.1002/cca.2631 ◽

2019 ◽

Author(s):

Jane Burch ◽

Gustavo Villalobos

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Vaccine Treatment ◽

PCN5 PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) COMPARED WITH COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE, AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER

Value in Health ◽

10.1016/s1098-3015(10)68916-4 ◽

2007 ◽

Vol 10 (3) ◽

pp. A124 ◽

Cited By ~ 1

Author(s):

WD Smith ◽

R Arbuckle

Keyword(s):

Renal Cell Carcinoma ◽

Combination Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Pharmacoeconomic Analysis ◽

Cancer Center ◽

Line Treatment ◽

First Line ◽

Optimising first-line treatment for metastatic renal cell carcinoma

The Lancet ◽

10.1016/s0140-6736(19)32495-x ◽

2020 ◽

Vol 395 (10219) ◽

pp. e7

Author(s):

Guillermo de Velasco

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Optimising first-line treatment for metastatic renal cell carcinoma

The Lancet ◽

10.1016/s0140-6736(19)32594-2 ◽

2020 ◽

Vol 395 (10219) ◽

pp. e8 ◽

Cited By ~ 1

Author(s):

Fei Liang

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽